This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2012 Financial Results

Total revenues and other income increased to $3,000 for the year ended December 31, 2012 as compared to $2,000 for the same period in the prior year. This increase is primarily due to an increase in interest income due to higher cash balances.

As of December 31, 2012, the Company had 17,160,155 shares of common stock outstanding. On January 29, 2013, 872,133 Series A Warrants and 713,741 Series B Warrants were exercised using the cashless exercise provision of the Warrant Agreements, resulting in the issuance of 1,483,831 shares of our common stock. As a result of this exercise, we currently have 18,643,986 shares of common stock outstanding.

About Repros Therapeutics Inc. ®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund development of its Androxal® and Proellex® programs and have success in the clinical development of its technologies, the reliability of interim results to predict final study outcomes, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com .

The Repros Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7738

 
REPROS THERAPEUTICS INC. AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
         
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
         
  Three Months Ended Twelve Months Ended
  December 31, December 31,
  2012 2011 2012 2011
         
Revenues        
Interest income  $ 2  $ 1  $ 3  $ 2
Total revenues  2  1  3  2
         
Expenses        
Research and development  6,568  1,701  13,343  8,682
General and administrative  1,479  1,032  4,827  3,811
Total expenses  8,047  2,733  18,170  12,493
         
Net loss  $ (8,045)  $ (2,732)  $ (18,167)  $ (12,491)
         
Net loss per share - basic and diluted  $ (0.47)  $ (0.22)  $ (1.18)  $ (1.04)
         
Weighted average shares used in loss per share calculation:        
Basic  17,134  12,320  15,346  11,961
Diluted  17,134  12,320  15,346  11,961
         
         
CONSOLIDATED BALANCE SHEETS
(in thousands)
         
    December 31, December 31,  
    2012 2011  
         
         
Cash and cash equivalents    $ 24,212  $ 4,565  
Other currents assets    406  99  
Fixed assets (net)    53  15  
Other assets (net)    2,161  1,385  
Total assets    $ 26,832  $ 6,064  
         
Accounts payable and accrued expenses     $ 3,798  $ 1,398  
Stockholders' equity    23,034  4,666  
Total liabilities and stockholders' equity    $ 26,832  $ 6,064  
CONTACT: Joseph S. Podolski
         Chief Executive Officer
         (281) 719-3447
         
         Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931

company logo

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,078.11 -84.88 -0.47%
S&P 500 2,117.34 -6.14 -0.29%
NASDAQ 5,094.7820 -11.8110 -0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs